Mild Renal Impairment
| Dose Information |
|---|
Graph Information
Transitioning a Patient with Mild Renal Impairment to INVEGA TRINZA®
Consistent with the INVEGA TRINZA® Prescribing Information:
- INVEGA TRINZA® is to be used only after INVEGA SUSTENNA® has been established as adequate treatment for at least four months.
- In order to establish a consistent maintenance dose, it is recommended that the last two doses of INVEGA SUSTENNA® be the same dosage strength before starting INVEGA TRINZA®.
- INVEGA TRINZA® has not been systematically studied in patients with renal impairment. INVEGA TRINZA® is not recommended in patients with moderate or severe renal impairment (creatinine clearance <50 mL/min).
- For patients with mild renal impairment (creatinine clearance ≥50 mL/min to <80 mL/min [Cockcroft-Gault Formula], adjust dosage and stabilize the patient using INVEGA SUSTENNA®, then transition to INVEGA TRINZA® using the equivalent 3.5-fold higher dose as shown in the table below.
- While
the INVEGA TRINZA® Prescribing Information does permit a dosing window to avoid
a first INVEGA TRINZA® missed dose, in this scenario, the timing of the first
INVEGA TRINZA® dose is locked and cannot be adjusted ±7 days.
INVEGA TRINZA® Doses for Adult Patients Adequately Treated with INVEGA SUSTENNA®
|
If the Last Dose of INVEGA SUSTENNA® is: |
Initiate INVEGA TRINZA® at the Following Dose: |
|
78 mg |
273 mg |
|
117 mg |
410 mg |
|
156 mg |
546 mg |
|
234 mg |
819 mg |
Conversion from the INVEGA SUSTENNA® 39 mg dose was not studied.
- INVEGA TRINZA® should be administered every 3 months.
- Administration: For intramuscular injection only by a healthcare professional. Care should be taken to avoid inadvertent injection into a blood vessel.
INVEGA TRINZA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf]